BOLLINGER INNOVATIONS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that BOLLINGER INNOVATIONS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $60.06M | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | $54.29M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $40.24M | Oct 19, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2024 | $1.09M | Jan 24, 2025 |
| FY2024 | Sep 30, 2023 | $366.0K | Jan 24, 2025 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $60.06M | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | $54.29M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $40.24M | Oct 19, 2017 |
| FY2015 | Dec 31, 2014 | $21.24M | Jun 27, 2016 |
| FY2014 | Dec 31, 2013 | $18.75M | Mar 30, 2015 |
| FY2013 | Dec 31, 2012 | $1.38M | Apr 15, 2014 |
| FY2012 | Dec 31, 2011 | $183.2K | Apr 12, 2013 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2024 | ($15.80M) | Jan 24, 2025 |
| FY2024 | Sep 30, 2023 | $92.1K | Jan 24, 2025 |
| FY2020 | Dec 31, 2020 | $9.84M | Mar 31, 2021 |
| FY2020 | Dec 31, 2019 | $10.28M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $10.17M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $8.83M | Apr 1, 2019 |
| FY2016 | Dec 31, 2016 | $8.58M | Oct 19, 2017 |
| FY2016 | Dec 31, 2015 | $6.26M | Oct 19, 2017 |
| FY2015 | Dec 31, 2014 | $5.31M | Jun 27, 2016 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2024 | ($457.06M) | Jan 24, 2025 |
| FY2024 | Sep 30, 2023 | ($972.25M) | Jan 24, 2025 |
| FY2023 | Sep 30, 2022 | ($739.53M) | Jan 17, 2024 |
| FY2022 | Jun 30, 2022 | ($27.93M) | Jan 30, 2023 |
| FY2022 | Mar 31, 2022 | ($324.61M) | Jan 30, 2023 |
| FY2022 | Dec 31, 2021 | ($156.06M) | Jan 30, 2023 |
| FY2022 | Sep 30, 2021 | ($44.24M) | Jan 30, 2023 |
| FY2020 | Dec 31, 2020 | ($5.94M) | Mar 31, 2021 |
| FY2021 | Sep 30, 2020 | ($30.18M) | Jan 10, 2022 |
| FY2020 | Dec 31, 2019 | ($6.46M) | Mar 31, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2024 | ($391.83M) | Jan 24, 2025 |
| FY2024 | Sep 30, 2023 | ($377.77M) | Jan 24, 2025 |
| FY2023 | Sep 30, 2022 | ($96.99M) | Jan 17, 2024 |
| FY2022 | Jun 30, 2022 | ($18.22M) | Jan 30, 2023 |
| FY2022 | Mar 31, 2022 | ($30.45M) | Jan 30, 2023 |
| FY2022 | Dec 31, 2021 | ($14.06M) | Jan 30, 2023 |
| FY2022 | Sep 30, 2021 | ($22.40M) | Jan 30, 2023 |
| FY2020 | Dec 31, 2020 | ($4.49M) | Mar 31, 2021 |
| FY2021 | Sep 30, 2020 | ($12.09M) | Jan 10, 2022 |
| FY2020 | Dec 31, 2019 | ($5.59M) | Mar 31, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2024 | $74.89M | Jan 24, 2025 |
| FY2024 | Sep 30, 2023 | $77.39M | Jan 24, 2025 |
| FY2023 | Sep 30, 2022 | $21.65M | Jan 17, 2024 |
| FY2022 | Sep 30, 2021 | $3.01M | Jan 30, 2023 |
| FY2021 | Sep 30, 2020 | $1.67M | Jan 10, 2022 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $7.02M | Mar 31, 2021 |
| FY2020 | Dec 31, 2019 | $9.34M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $9.76M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $10.63M | Apr 1, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2024 | ($185.56M) | Jan 24, 2025 |
| FY2024 | Sep 30, 2023 | ($179.17M) | Jan 24, 2025 |
| FY2023 | Sep 30, 2022 | ($65.80M) | Jan 17, 2024 |
| FY2022 | Sep 30, 2021 | ($17.52M) | Jan 30, 2023 |
| FY2020 | Dec 31, 2020 | $3.02M | Mar 31, 2021 |
| FY2021 | Sep 30, 2020 | ($10.78M) | Jan 10, 2022 |
| FY2020 | Dec 31, 2019 | ($2.15M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($3.27M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($5.07M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($3.28M) | Apr 2, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2024 | $14.75M | Jan 24, 2025 |
| FY2024 | Sep 30, 2023 | $14.51M | Jan 24, 2025 |
| FY2023 | Sep 30, 2022 | $11.61M | Jan 17, 2024 |
| FY2021 | Nov 12, 2021 | $12.00M | Jan 10, 2022 |
| FY2022 | Sep 30, 2021 | $43.9K | Jan 30, 2023 |
| FY2021 | Sep 30, 2020 | $270.5K | Jan 10, 2022 |
| FY2019 | Dec 31, 2019 | $138.0K | Mar 30, 2020 |
| FY2019 | Dec 31, 2018 | $114.9K | Mar 30, 2020 |
| FY2017 | Dec 31, 2017 | $103.3K | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | $187.1K | Apr 2, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2024 | $178.63M | Jan 24, 2025 |
| FY2024 | Sep 30, 2023 | $421.71M | Jan 24, 2025 |
| FY2023 | Sep 30, 2022 | $302.59M | Jan 17, 2024 |
| FY2022 | Jun 30, 2022 | $84.26M | Jan 30, 2023 |
| FY2022 | Mar 31, 2022 | $105.21M | Jan 30, 2023 |
| FY2022 | Dec 31, 2021 | $45.41M | Jan 30, 2023 |
| FY2022 | Sep 30, 2021 | $17.17M | Jan 30, 2023 |
| FY2020 | Dec 31, 2020 | $26.83M | Mar 31, 2021 |
| FY2021 | Sep 30, 2020 | $21.99M | Jan 10, 2022 |
| FY2020 | Dec 31, 2019 | $23.04M | Mar 31, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2024 | $195.18M | Jan 24, 2025 |
| FY2024 | Sep 30, 2023 | $148.90M | Jan 24, 2025 |
| FY2023 | Sep 30, 2022 | $145.64M | Jan 17, 2024 |
| FY2022 | Jun 30, 2022 | $48.15M | Jan 30, 2023 |
| FY2022 | Mar 31, 2022 | $259.61M | Jan 30, 2023 |
| FY2022 | Dec 31, 2021 | $175.50M | Jan 30, 2023 |
| FY2022 | Sep 30, 2021 | $78.88M | Jan 30, 2023 |
| FY2020 | Dec 31, 2020 | $24.34M | Mar 31, 2021 |
| FY2021 | Sep 30, 2020 | $64.49M | Jan 10, 2022 |
| FY2020 | Dec 31, 2019 | $19.00M | Mar 31, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2024 | ($28.56M) | Jan 24, 2025 |
| FY2024 | Sep 30, 2023 | $208.95M | Jan 24, 2025 |
| FY2023 | Sep 30, 2022 | $58.70M | Jan 17, 2024 |
| FY2021 | Sep 30, 2021 | ($61.71M) | Jan 10, 2022 |
| FY2021 | Sep 30, 2020 | ($42.50M) | Jan 10, 2022 |
| FY2021 | Sep 30, 2019 | ($33.88M) | Jan 10, 2022 |
| FY2011 | Dec 31, 2011 | $22.70M | Apr 12, 2012 |
| FY2011 | Dec 31, 2010 | $23.37M | Apr 12, 2012 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2024 | $0 | Jan 24, 2025 |
| FY2024 | Sep 30, 2023 | $28.85M | Jan 24, 2025 |
| FY2024 | Sep 30, 2022 | $92.83M | Jan 24, 2025 |
| FY2022 | Sep 30, 2021 | $0 | Jan 30, 2023 |
| FY2020 | Dec 31, 2020 | $7.68M | Mar 31, 2021 |
| FY2020 | Dec 31, 2019 | $7.68M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $9.01M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $9.64M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $9.64M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $9.64M | Oct 19, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2024 | ($2.32B) | Jan 24, 2025 |
| FY2024 | Sep 30, 2023 | ($1.86B) | Jan 24, 2025 |
| FY2023 | Sep 30, 2022 | ($889.91M) | Jan 17, 2024 |
| FY2022 | Jun 30, 2022 | ($635.89M) | Jan 30, 2023 |
| FY2022 | Mar 31, 2022 | ($631.04M) | Jan 30, 2023 |
| FY2022 | Dec 31, 2021 | ($306.44M) | Jan 30, 2023 |
| FY2022 | Sep 30, 2021 | ($150.37M) | Jan 30, 2023 |
| FY2020 | Dec 31, 2020 | ($184.69M) | Mar 31, 2021 |
| FY2021 | Sep 30, 2020 | ($106.13M) | Jan 10, 2022 |
| FY2020 | Dec 31, 2019 | ($178.75M) | Mar 31, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2024 | $10.32M | Jan 24, 2025 |
| FY2024 | Sep 30, 2023 | $155.27M | Jan 24, 2025 |
| FY2023 | Sep 30, 2022 | $54.09M | Jan 17, 2024 |
| FY2022 | Sep 30, 2021 | $42.2K | Jan 30, 2023 |
| FY2020 | Dec 31, 2020 | $4.54M | Mar 31, 2021 |
| FY2021 | Sep 30, 2020 | $33.4K | Jan 10, 2022 |
| FY2020 | Dec 31, 2019 | $486.6K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $1.65M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $11.29M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $621.6K | Apr 2, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2024 | $5.40M | Jan 24, 2025 |
| FY2024 | Sep 30, 2023 | $7.46M | Jan 24, 2025 |
| FY2024 | Sep 30, 2022 | $9.02M | Jan 24, 2025 |
| FY2021 | Sep 30, 2021 | $39.45M | Jan 10, 2022 |
| FY2020 | Dec 31, 2020 | $9.94M | Mar 31, 2021 |
| FY2021 | Sep 30, 2020 | $33.33M | Jan 10, 2022 |
| FY2020 | Dec 31, 2019 | $9.25M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $6.38M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $7.02M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $4.42M | Apr 2, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2024 | (1,425) | Jan 24, 2025 |
| FY2024 | Sep 30, 2023 | (157,405) | Jan 24, 2025 |
| FY2023 | Sep 30, 2022 | (63,085) | Jan 17, 2024 |
| FY2022 | Jun 30, 2022 | 0 | Jan 30, 2023 |
| FY2022 | Mar 31, 2022 | (6) | Jan 30, 2023 |
| FY2022 | Dec 31, 2021 | (8) | Jan 30, 2023 |
| FY2022 | Sep 30, 2021 | (8) | Jan 30, 2023 |
| FY2021 | Sep 30, 2020 | (5) | Jan 10, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Sep 30, 2023 | (1,574) | Jan 17, 2024 |
| FY2023 | Sep 30, 2022 | (63,083) | Jan 17, 2024 |
| FY2022 | Sep 30, 2021 | (8) | Jan 30, 2023 |
| FY2021 | Sep 30, 2020 | (5) | Jan 10, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2024 | 4.58M | Jan 24, 2025 |
| FY2024 | Sep 30, 2023 | 28,718 | Jan 24, 2025 |
| FY2023 | Sep 30, 2022 | 37,043 | Jan 17, 2024 |
| FY2022 | Sep 30, 2021 | 7.05M | Jan 30, 2023 |
| FY2020 | Dec 31, 2020 | 5.00M | Mar 31, 2021 |
| FY2021 | Sep 30, 2020 | 5.09M | Jan 10, 2022 |
| FY2020 | Dec 31, 2019 | 4.11M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 3.86M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 3.85M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 1.54M | Apr 2, 2018 |